Human stem cells used to cure renal anemia in mice

September 28, 2017 by Bob Yirka, Medical Xpress report
Microscopic images of stem-cell derived EPO-producing cells that were used to treat renal anemia in mice. Credit: H. Hitomi et al., Science Translational Medicine (2017)

(Medical Xpress)—A team of researchers with Kyoto University and Kagawa University, both in Japan, has cured renal anemia in mice by injecting them with treated human stem cells. In their paper published in Science Translational Medicine, the group describes their approach and how well it worked.

Chronic kidney disease is a serious ailment resulting in a host of symptoms due to the body's reduced ability to process waste and fluids—many patients eventually experience , which requires them to undergo routine dialysis or a kidney transplant. Less well known is that people with also suffer from renal anemia because the kidneys manufacture the hormone erythropoietin (EPO), which causes the body to produce without which the blood cannot carry enough oxygen to the brain and other body parts. The current treatment for renal anemia is injections of EPO every few days, which, for many people, is impractical because of the cost and side effects. In this new effort, the researchers have found a possible new treatment—injecting treated directly into the kidneys.

In their experiments, the researchers collected stem cells from human cord blood (from the umbilical cord) and then treated them with growth factors that changed them to that grew into mature cells capable of producing EPO. The team then injected the treated cells into the kidneys of mice suffering from renal anemia and monitored them for the rest of their lives.

Progressively zoomed-in images of stem-cell derived EPO-producing cells and mouse liver for comparison (bottom right), showing secretory structures called vesicles (indicated by arrows). Credit: H. Hitomi et al., Science Translational Medicine (2017)

The team reports that for all of the mice tested, EPO levels were approximately 20 times higher than for control mice after just four weeks—putting them in the normal range. They report also that the levels were maintained through the life of the mice, which, the team notes, means they were cured of the ailment.

It is not clear yet, of course, whether the procedure would work with human patients, but the group intends to continue their research with the goal of finding out. If the procedure works as intended and does not cause harmful side effects, people in the future suffering from kidney disease may no longer have to worry about also dealing with anemia.

Images of blood cells forming in response to purified EPO protein from conventional sources (left) and from stem-cell derived EPO producing cells (left). Credit: H. Hitomi et al., Science Translational Medicine (2017)

Explore further: Fixing common blood disorder would make kidney transplants more successful

More information: Hirofumi Hitomi et al. Human pluripotent stem cell–derived erythropoietin-producing cells ameliorate renal anemia in mice, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aaj2300

Abstract
The production of erythropoietin (EPO) by the kidneys, a principal hormone for the hematopoietic system, is reduced in patients with chronic kidney disease (CKD), eventually resulting in severe anemia. Although recombinant human EPO treatment improves anemia in patients with CKD, returning to full red blood cell production without fluctuations does not always occur. We established a method to generate EPO-producing cells from human induced pluripotent stem cells (hiPSCs) by modifying previously reported hepatic differentiation protocols. These cells showed increased EPO expression and secretion in response to low oxygen conditions, prolyl hydroxylase domain–containing enzyme inhibitors, and insulin-like growth factor 1. The EPO protein secreted from hiPSC-derived EPO-producing (hiPSC-EPO) cells induced the erythropoietic differentiation of human umbilical cord blood progenitor cells in vitro. Furthermore, transplantation of hiPSC-EPO cells into mice with CKD induced by adenine treatment improved renal anemia. Thus, hiPSC-EPO cells may be a useful tool for clarifying the mechanisms of EPO production and may be useful as a therapeutic strategy for treating renal anemia.

Related Stories

Fixing common blood disorder would make kidney transplants more successful

December 22, 2011
Correcting anemia, a red blood cell deficiency, can preserve kidney function in many kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). ...

Green mamba peptide found to reduce symptoms of kidney disease in mice

June 20, 2017
(Medical Xpress)—A team of researchers from France, Germany and Belgium has found that giving a peptide found in green mamba venom to mice with a kidney disease led to reduced symptoms. In their paper published in Proceedings ...

Induced pluripotent stem cells show promise for kidney treatment

July 21, 2015
One promising way to treat diseased or damaged kidneys is cell therapies that include the transplantation of renal progenitor cells, which can then develop into the cells needed for full recovery. Acquiring a sufficient number ...

Common virus may cause anemia in patients with kidney disease

April 10, 2014
A virus that is present in most people in a latent state may induce or exacerbate anemia in patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology ...

Stem cell-derived kidneys connect to blood vessels when transplanted into mice

November 19, 2015
Various research groups are collecting different types of cells and turning them into induced pluripotent stem (iPS) cells that can then generate diverse types of cells and tissues in the body. Now investigators have transplanted ...

Recommended for you

Enzyme identified as possible novel drug target for sickle cell disease, Thalassemia

July 19, 2018
Medical researchers have identified a key signaling protein that regulates hemoglobin production in red blood cells, offering a possible target for a future innovative drug to treat sickle cell disease (SCD). Experiments ...

Mice given metabolite succinate found to lose weight by turning up the heat

July 19, 2018
A team of researchers with members from institutions across the U.S. and Canada has found that giving the metabolite succinate to mice fed a high-fat diet prevented obesity. In their paper published in the journal Nature, ...

Supplement may ease the pain of sickle cell disease

July 19, 2018
(HealthDay)—An FDA-approved supplement reduces episodes of severe pain in people with sickle cell disease, a new clinical trial shows.

Scientists uncover DNA 'shield' with crucial roles in normal cell division

July 18, 2018
Scientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.

Researchers develop novel bioengineering technique for personalized bone grafts

July 18, 2018
Scientists from the New York Stem Cell Foundation (NYSCF) Research Institute have developed a new bone engineering technique called Segmental Additive Tissue Engineering (SATE). The technique, described in a paper published ...

Researchers report protein kinase as the switch controlling obesity and diabetes

July 18, 2018
One of the research lines targeting the worldwide obesity epidemic is the manipulation of brown adipose tissue, a 'good' type of fat that burns lipids to maintain an appropriate body temperature. Researchers at the Centro ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.